Evidence map›Paper›PMID 41792865›Full record

Trial reportClinical and translational science2026

Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor.

Simon J Shaw, Vanessa C Taylor, Jonathan T Sims, Stephen Ho, Chrystelle Lamagna, Lucy Yan, Nicholas C Reising, Andrew Chow, Eric P Hanson, Andrew C Vendel and 2 more

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Simon J ShawRigel Pharmaceuticals, Inc., South San Francisco, California, USA.ORCID 0000-0002-0548-1881
Vanessa C TaylorRigel Pharmaceuticals, Inc., South San Francisco, California, USA.ORCID 0009-0009-8163-1827
Jonathan T SimsImmunology Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-8599-2157
Stephen HoImmunology Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.
Chrystelle LamagnaRigel Pharmaceuticals, Inc., South San Francisco, California, USA.ORCID 0009-0004-7557-5535
Lucy YanRigel Pharmaceuticals, Inc., South San Francisco, California, USA.
Nicholas C ReisingNeuroscience Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.
Andrew ChowRigel Pharmaceuticals, Inc., South San Francisco, California, USA.ORCID 0009-0006-2064-2424
Eric P HansonImmunology Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0002-0318-4779
Andrew C VendelImmunology Discovery, Eli Lilly and Company, San Diego, California, USA.ORCID 0009-0002-6466-348X
Daniel J DairaghiImmunology Discovery, Eli Lilly and Company, Indianapolis, Indiana, USA.
Esteban S MasudaRigel Pharmaceuticals, Inc., South San Francisco, California, USA.ORCID 0000-0002-3175-2868

Funding

Eli Lilly and CompanyRigel Pharmaceuticals
6 · The paper itself

Abstract

Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials. Here, we present data on the development of ocadusertib, including preclinical studies and pharmacokinetic, safety, and target engagement results from phase 1 trials. Preclinically, ocadusertib inhibited RIPK1 enzymatic activity with high potency (half-maximal inhibitory concentration [IC

Indexed as

Protein Kinase InhibitorsPyrazolesReceptor-Interacting Protein Serine-Threonine KinasesAdultAnimalsDisease Models, AnimalDouble-Blind MethodDrug Evaluation, PreclinicalFemaleHumansMaleMiceOxazepinesTriazolesGSK2982772OxazepinesProtein Kinase InhibitorsPyrazolesReceptor-Interacting Protein Serine-Threonine KinasesRIPK1 protein, humanTriazolesclinical trialshealthy subjectsinhibitorspharmacokineticsphase 1preclinicalRIPK1safety

Identifiers

PMID41792865
PMCPMC12965899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.